ライフサイエンスコーパス: all patients who received

1 the modified intention-to-treat population, which included all patients who received at least one day of treatment.

2 Safety analysis was done in all patients who received at least one dose of avelumab.

3 The primary endpoint was assessed in all patients who received at least one dose of combination th

4 and tolerability were assessed in the safety analysis set (all patients who received at least one dose of gilteritinib).

5 Activity and safety were analysed in all patients who received at least one dose of pembrolizumab

6 We assessed efficacy and safety in all patients who received at least one dose of study drug (in

7 Responses were assessed in the full analysis set (all patients who received at least one dose of study drug and

8 Safety was assessed in all patients who received at least one dose of study drug and

9 tention-to-treat population, whereas safety was analysed in all patients who received at least one dose of study drug and

10 Safety was analysed in all patients who received at least one dose of study drug and

11 All patients who received at least one dose of study drug wer

12 mpty from the stomach), measured at 5 weeks and 16 weeks in all patients who received at least one dose of study drug, wi

13 Safety analyses were done in all patients who received at least one dose of study drug.

14 Safety was analysed in all patients who received at least one dose of study drug.

15 Adverse events were assessed in all patients who received at least one dose of study drug.

16 ed by intention to treat and the safety population included all patients who received at least one dose of study drug.

17 sis was by intention to treat, and safety analysis included all patients who received at least one dose of study drug.

18 We assessed safety in all patients who received at least one dose of study drug.

19 The safety population included all patients who received at least one dose of study drug.

20 cale-Revised) and overall survival, analysed at 48 weeks in all patients who received at least one dose of study drug.

21 ith SVR12; the primary endpoint and safety were assessed in all patients who received at least one dose of study drugs.

22 he intention-to-treat population and safety was assessed in all patients who received at least one dose of study treatmen

23 n the intention-to-treat population; safety was analysed in all patients who received at least one dose of study treatmen

24 The key exploratory PRO endpoints (analysed for all patients who received at least one dose of study treatmen

25 up HSCT) and after study treatment and subsequent HSCT, for all patients who received at least one dose of study treatmen

26 Safety was assessed in all patients who received at least one dose of study treatmen

27 The efficacy analysis included all patients who received at least one dose of the randomised

28 andomly assigned to treatment; safety analyses were done in all patients who received at least one dose of the study drug

29 icity were analysed in the safety population, consisting of all patients who received at least one dose of their randomis

30 Safety was assessed in all patients who received at least one dose of trial medicati

31 All patients who received at least one dose of venetoclax wer

32 r protocol for all patients who commenced drug and included all patients who received at least one dose of venetoclax.

33 All patients who received at least one dose were included in

34 ine in PSA concentration from baseline (PSA50) for BAT (for all patients who received at least one dose) and for enzaluta

35 Safety was assessed in all patients who received at least one injection of study med

36 analyses were done in the safety population, consisting of all patients who received at least one study drug dose and on

37 All patients who received DEX between January 14, 2013, and A

38 All patients who received HAI also received perioperative sys

39 ow-up, echocardiography confirmed mild or no residual MR in all patients who received implants.

40 All patients who received massive transfusions within the stu

41 ts admitted to the ICU but have limited ability to identify all patients who received mechanical ventilation during a cri

42 We assessed safety in all patients who received one or more doses of BIIB074.

43 Safety was assessed in all patients who received one or more doses of the study drug

44 All patients who received study intervention (injection of dy

45 Safety was assessed in all patients who received the intervention.

46 Safety analyses included all patients who received the study drug (ADS-5102 or placebo

47 Safety was analysed in all patients who received the surgical implantation except in

48 ention-to-treat population) and adverse events (analysed in all patients who received treatment and submitted adverse eve

49 All patients who received treatment were included in an inten

50 Toxicity was analysed in all patients who received trial treatment.